Fosamax and Osteonecrosis of the Jaw: Causation and Risk Assessment

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Health Information and Transition to Occupational Concerns

The legacy of general health and science information has long provided a foundational framework for understanding how therapeutic interventions interact with human physiology. Within this broad context, the dissemination of knowledge regarding medication safety and adverse effects has been a cornerstone, enabling both clinicians and patients to make informed decisions. This heritage includes the careful monitoring of pharmaceutical outcomes, where the balance between benefit and risk is continuously evaluated. As such, the historical focus on general health literacy has prepared the ground for more specialized inquiries into specific drug-tissue interactions, particularly when unexpected complications arise from long-term use. Transitioning from this broad informational base, attention now turns to a more focused domain: the occupational exposure concern. While the initial recognition of an association between bisphosphonate therapy, such as Fosamax, and osteonecrosis of the jaw emerged from clinical pharmacovigilance, the implications extend beyond the patient population. In occupational settings, individuals may encounter similar compounds or conditions that heighten risk, necessitating a shift in perspective. This pivot requires examining how legacy health information can be adapted to address workplace hazards, where chronic exposure to certain agents may mirror the biological pathways observed in therapeutic contexts. The concern thus moves from general patient education to specific occupational health surveillance, emphasizing the need for targeted risk assessment and preventive strategies in environments where exposure to such agents is a routine part of professional activity.

Fosamax Pharmacology and Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing the incidence of fractures, including those of the hip and spine (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and exposed bone in the jaw, which may be accompanied by purulent discharge or fistula formation. Diagnosis is typically based on clinical examination and imaging, with a history of bisphosphonate use being a key factor. The pharmacology of Fosamax provides insight into the mechanistic pathways linking it to ONJ. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which is their intended therapeutic effect. However, this suppression of bone turnover can lead to impaired bone remodeling and repair, particularly in the jawbone, which has high metabolic activity and is subject to frequent microtrauma from chewing and dental procedures. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has shown that bisphosphonate treatment affects the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These changes may predispose the jawbone to necrosis, especially when combined with local factors such as infection or dental surgery.

Timeline, Risk Factors, and Warning Adequacy

The time to onset of ONJ symptoms after starting Fosamax varies widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a clear timeline between exposure and documented harm. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that ONJ is a rare event that may be influenced by individual risk factors. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section advises that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the warning also notes that most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, the rare nature of ONJ and the variability in onset may lead to under-recognition in clinical practice.

Causation Considerations and Clinical Implications

For affected patients, causation considerations are complex. The association between Fosamax and ONJ is supported by pharmacovigilance data and mechanistic plausibility, but establishing individual causation requires careful evaluation of temporal relationship, exclusion of other causes, and consideration of risk factors. The timeline between exposure and harm is not fixed, with onset ranging from days to months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability means that patients who develop ONJ after long-term use may have a stronger association than those with short-term exposure. Additionally, the presence of other risk factors, such as dental procedures or concomitant medications, may confound the relationship. In summary, Fosamax is linked to osteonecrosis of the jaw through pharmacological mechanisms that suppress bone turnover, with evidence from clinical reports and preclinical studies. The risk is increased by duration of exposure and presence of other risk factors. Warnings in the prescribing information address this risk, but the rare and variable nature of ONJ poses challenges for timely diagnosis and management. Patients and healthcare providers should be aware of the signs and symptoms of ONJ and consider preventive dental care before initiating bisphosphonate therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that suppresses bone turnover, which can lead to impaired bone remodeling in the jaw, increasing the risk of osteonecrosis of the jaw (ONJ). This association is supported by pharmacovigilance data and mechanistic studies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset varies widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.